MedTrace Logo

Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study

NCT07622108 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-06-04

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.

Conditions

  • Thyroid Eye Disease, TED

Interventions

DRUG

MHB018A

MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

DRUG

MHB018A placebo

6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)

Sponsors & Collaborators

  • Minghui Pharmaceutical (Hangzhou) Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-31
Primary Completion
2028-07-31
Completion
2029-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07622108 on ClinicalTrials.gov